Table 1. Patient characteristics between T790M+ and T790M− groups (n = 51).
| Characteristic | Total (n = 51) | T790M+ | T790M− | P |
|---|---|---|---|---|
| (n = 18) n (%) | (n = 33) n (%) | |||
| Age (year) | 0.171 | |||
| Median (Range) | 58 (30~87) | 58 (44~87) | 57 (30~82) | |
| Gender | 0.164 | |||
| Male | 19 (37.3) | 9 (50.0) | 10 (30.3) | |
| Female | 32 (62.7) | 9 (50.0) | 23 (69.7) | |
| Smoking status | 1.000 | |||
| Smoker | 8 (15.7) | 3 (16.7) | 5 (15.2) | |
| Never smoker | 43 (84.3) | 15 (83.3) | 28 (84.8) | |
| ECOG performance status | 1.000 | |||
| 0~1 | 37 (72.5) | 13 (72.2) | 24 (72.7) | |
| ≥ 2 | 14 (27.5) | 5 (27.8) | 9 (27.3) | |
| Insertion chemotherapy | 0.288 | |||
| None | 11 (21.6) | 2 (11.1) | 9 (27.3) | |
| Cytotoxic chemo | 40 (78.4) | 16 (88.9) | 24 (72.7) | |
| EGFR mutation | 0.217 | |||
| Exon 19 deletion | 31 (60.8) | 13 (72.2) | 18 (54.5) | |
| Exon 21 L858R mutation | 20 (39.2) | 5 (27.8) | 15 (45.5) | |
| TKI-free interval | 0.137 | |||
| < 3 m | 10 (19.6) | 6 (33.3) | 4 (12.1) | |
| ≥ 3 m | 41 (80.4) | 12 (66.7) | 29 (87.9) | |
| PFS of initial TKI | 0.726 | |||
| <6 m | 11 (21.6) | 3 (16.7) | 8 (24.2) | |
| ≥ 6 m | 40 (78.4) | 15 (83.3) | 25 (75.8) | |
| Secondary EGFR-TKIs | 0.690 | |||
| Erlotinib | 33 (64.7) | 11 (61.1) | 22 (66.7) | |
| Gefitinib | 18 (35.3) | 7 (38.9) | 11 (33.3) | |
| Line of TKI re-challenge | 1.000 | |||
| Second line | 6 (11.8) | 2 (11.1) | 4 (12.1) | |
| ≥ Second line | 45 (88.2) | 16 (88.9) | 29 (87.9) | |
| EGFR detection assay | 0.880 | |||
| Seq | 36 (70.6) | 12 (66.6) | 24 (72.7) | |
| ARMS | 12 (23.5) | 5 (27.8) | 7 (21.2) | |
| Seq+ARMS | 3 (5.9) | 1 (5.6) | 2 (6.1) | |
| Progression model of initial TKI | 0.849 | |||
| Dramatic | 19 (37.2) | 7 (38.8) | 12 (36.3) | |
| Local | 15 (29.4) | 5 (27.8) | 10 (30.3) | |
| Gradual | 6 (11.8) | 3 (16.7) | 3 (9.1) | |
| Unknown* | 11 (21.6) | 3 (16.7) | 8 (24.2) |
PFS, progression-free survival. Seq, Sanger sequencing. ARMS, Amplification Refractory Mutation System.*These patients were initiated with TKIs in other hospitals.